On November 10,2023, the "Innovation Jiangsu" Innovation and Entrepreneurship Competition was held in Jiangbei New District, Nanjing. In order to lay out new tracks, cultivate new advantages and accelerate the gathering of innovative and entrepreneurial talents, this "Innovation Jiangsu" Innovation and Entrepreneurship Competition, with the theme of "self-reliance and development through science and innovation", focuses on the field of life science, attracting active participation from universities, excellent entrepreneurial teams and scientific research institutions.

Since its launch, the competition has attracted high-quality projects from all over the country. The entries cover biomedicine, medical devices, life and health and other subsectors, showing high innovation and practicality. After layers of screening, a total of 15 projects advanced to the final.


Chomix biochemical proteomics project stood out in the fierce competition and won the first prize of 2023 "Technology Innovation Jiangsu" Innovation Group.


The final won wide attention from all walks of life. Chen Hongyuan, academician of Chinese Academy of Sciences and professor of Nanjing University, Zhu Jun, Secretary of Party Group and Chairman of Nanjing Association for Science and Technology, Chen Wenbin, member of Party Working Committee of Nanjing Jiangbei New District and Deputy Director of Management Committee, and Ma Litao, director of Service Center of Jiangsu Society attended the award ceremony.

About ChomiX

As a leading biotechnology company, ChomiX Biotech Co., Ltd is dedicated to advancing the preclinical development of innovative small molecule drugs. At the heart of our mission lies chemoproteomics, our core technology, which empowers us to rapidly break through the barriers of undruggable targets and accelerate the discovery of innovative small molecule drugs.

Founded in 2021, ChomiX has established multiple intersecting platforms spanning chemical biology, bioinformatics, medicinal chemistry, molecular and cell biology, etc. These multidisciplinary platforms provide a versatile suite of applications that advance drug discovery, from addressing undruggable targets to unraveling novel mechanisms behind known drugs. Our commitment to innovation also shines through a portfolio of chemoproteomics-related patents and a state-of-art laboratory equipped with a variety of cutting-edge instruments.

Post time: Nov-22-2023